全文获取类型
收费全文 | 46421篇 |
免费 | 3335篇 |
国内免费 | 494篇 |
专业分类
耳鼻咽喉 | 526篇 |
儿科学 | 1528篇 |
妇产科学 | 1053篇 |
基础医学 | 5648篇 |
口腔科学 | 668篇 |
临床医学 | 7362篇 |
内科学 | 7983篇 |
皮肤病学 | 668篇 |
神经病学 | 4234篇 |
特种医学 | 1029篇 |
外国民族医学 | 4篇 |
外科学 | 4481篇 |
综合类 | 1369篇 |
现状与发展 | 1篇 |
一般理论 | 50篇 |
预防医学 | 5947篇 |
眼科学 | 569篇 |
药学 | 3173篇 |
4篇 | |
中国医学 | 385篇 |
肿瘤学 | 3568篇 |
出版年
2024年 | 33篇 |
2023年 | 393篇 |
2022年 | 406篇 |
2021年 | 1196篇 |
2020年 | 841篇 |
2019年 | 1210篇 |
2018年 | 1400篇 |
2017年 | 1069篇 |
2016年 | 1111篇 |
2015年 | 1298篇 |
2014年 | 1720篇 |
2013年 | 2526篇 |
2012年 | 3576篇 |
2011年 | 3817篇 |
2010年 | 2072篇 |
2009年 | 1815篇 |
2008年 | 3206篇 |
2007年 | 3240篇 |
2006年 | 3205篇 |
2005年 | 3111篇 |
2004年 | 2745篇 |
2003年 | 2485篇 |
2002年 | 2312篇 |
2001年 | 411篇 |
2000年 | 374篇 |
1999年 | 459篇 |
1998年 | 568篇 |
1997年 | 454篇 |
1996年 | 347篇 |
1995年 | 289篇 |
1994年 | 282篇 |
1993年 | 245篇 |
1992年 | 227篇 |
1991年 | 173篇 |
1990年 | 160篇 |
1989年 | 133篇 |
1988年 | 143篇 |
1987年 | 126篇 |
1986年 | 122篇 |
1985年 | 113篇 |
1984年 | 116篇 |
1983年 | 92篇 |
1982年 | 98篇 |
1981年 | 117篇 |
1980年 | 80篇 |
1979年 | 61篇 |
1978年 | 34篇 |
1977年 | 42篇 |
1976年 | 36篇 |
1975年 | 25篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
目的 通过网络药理学的方法进行预测,再深一步进行动物实验验证来研究柴胡疏肝散治疗CAG的作用机制。方法 首先在TCMSP数据库中检索柴胡疏肝散的所有活性成分与药物靶点;通过收集PharmGkb、OMIM、GeneCards和DrugBank数据库中收录的慢性萎缩性胃炎的相关靶点。将药物靶点与疾病靶点进行映射筛选出交集靶点,将得到的交集靶点构建PPI网络与活性成分-共同靶点网络,并对其进行GO和KEGG富集分析。最后利用Vina软件进行分子对接实验验证,并通过免疫印迹法验证柴胡疏肝散对两种受体蛋白EGFR和STAT1的影响。结果 最终筛选得到柴胡疏肝散活性成分104个,潜在靶点238个,与慢性萎缩性胃炎的交集靶点52个;GO与KEGG富集分析分别得到2166条目和148条目,主要涉及到JAK-STAT信号通路、TNF信号通路、HIF-1信号通路等;分子对接结果显示EGFR、STAT1两个靶点能够与核心活性成分能够自发结合成较为稳定的构像;免疫印迹法实验证明柴胡疏肝散能够降低大鼠胃黏膜组织EGFR和STAT1蛋白表达。结论 通过网络药理学和实验验证,发现柴胡疏肝散可能通过调节EGFR和STAT1蛋白表达来共同调控胃黏膜细胞增殖与凋亡,进而发挥着治疗慢性萎缩性胃炎的效果,为深入进行柴胡疏肝散治疗慢性萎缩性胃炎的作用机制研究提供新思路和新方法。 相似文献
2.
Karl Johnson Katherine W. Saylor Isabella Guynn Karen Hicklin Jonathan S. Berg Kristen Hassmiller Lich 《Genetics in medicine》2022,24(2):262-288
PurposeUnderstanding the value of genetic screening and testing for monogenic disorders requires high-quality, methodologically robust economic evaluations. This systematic review sought to assess the methodological quality among such studies and examined opportunities for improvement.MethodsWe searched PubMed, Cochrane, Embase, and Web of Science for economic evaluations of genetic screening/testing (2013-2019). Methodological rigor and adherence to best practices were systematically assessed using the British Medical Journal checklist.ResultsAcross the 47 identified studies, there were substantial variations in modeling approaches, reporting detail, and sophistication. Models ranged from simple decision trees to individual-level microsimulations that compared between 2 and >20 alternative interventions. Many studies failed to report sufficient detail to enable replication or did not justify modeling assumptions, especially for costing methods and utility values. Meta-analyses, systematic reviews, or calibration were rarely used to derive parameter estimates. Nearly all studies conducted some sensitivity analysis, and more sophisticated studies implemented probabilistic sensitivity/uncertainty analysis, threshold analysis, and value of information analysis.ConclusionWe describe a heterogeneous body of work and present recommendations and exemplar studies across the methodological domains of (1) perspective, scope, and parameter selection; (2) use of uncertainty/sensitivity analyses; and (3) reporting transparency for improvement in the economic evaluation of genetic screening/testing. 相似文献
3.
Karen Kayser Ariel Washington Lesley M. Harris Barbara Head 《Journal of psychosocial oncology》2021,39(1):17-34
Abstract
Purpose
Financial hardship can be a major cause of distress among persons with cancer, resulting in chronic stress and impacting physical and emotional health. This paper provides an analysis of the lived experience of cancer patients’ financial hardship from diagnosis to post-treatment. 相似文献4.
5.
6.
7.
Proteomic Profiling of Small Extracellular Vesicles Isolated from the Plasma of Vietnamese Patients with Non-Small Cell Lung Cancer Reveals Some Potential Biomarkers 下载免费PDF全文
Thao Phuong Bui Phuong Lan LeLinh Thi Tu Nguyen Le Trung ThoThai Hong Trinh 《Asian Pacific journal of cancer prevention》2022,23(6):1893-1900
Background: Considering the poor prognosis of non-small cell lung cancer (NSCLC), the objective of this study was to examine the potential of plasma-derived vesicles as a source of lung cancer-specific proteins. Extracellular vesicle (EV) cargos are specific to the source cells, hence they have the potential of being a source of cancer-specific proteins. Methods: The proteins differently expressed in cancer were determined and derived from EVs isolated from the plasma of NSCLC patients at the National Lung Hospital. To this end, purification was done using gel filtration chromatography and ultracentrifugation. In addition, nano liquid chromatography mass spectrometry (LC–MS/MS) was used for analyzing. Results: Fifty-seven EV-derived proteins related to NSCLC were highlighted in this research. Some of them have not been addressed before, such as EEF1A1 (elongation factor 1-α1), KPNB1 (Importin subunit beta 1), SRC (proto-oncogene tyrosine-protein kinase) and ACTC1 (actin, alpha cardiac muscle 1). This list was further confirmed through a comparison with ExoCarta and Vesiclepedia. Conclusion: This study is the first work to show the involvement of several novel proteins of small EV (EEF1A1, KPNB1, SRC, and ACTC1) in the progression of NSCLC. The results suggested that they could serve as novel biomarkers for non-small cell lung cancer in the future. 相似文献
8.
9.
10.
Can EGFR mutation status be reliably determined in pre‐operative needle biopsies from adenocarcinomas of the lung? 下载免费PDF全文
Kim Hein Lindahl Flemming Brandt Sørensen Søren Peter Jonstrup Karen Ege Olsen Siegfried Loeschke 《APMIS : acta pathologica, microbiologica, et immunologica Scandinavica》2015,123(4):289-297
The identification of EGFR mutations in non‐small‐cell lung cancer is important for selecting patients, who may benefit from treatment with EGFR tyrosine kinase inhibitors. The analysis is usually performed on cytological aspirates and/or histological needle biopsies, representing a small fraction of the tumour volume. The aim of the present investigation was to evaluate the diagnostic performance of this molecular test. We retrospectively included 201 patients with primary adenocarcinoma of the lung. EGFR mutation status (exon 19 deletions and exon 21 L858R point mutation) was evaluated on both pre‐operative biopsies (131 histological and 70 cytological) and on the surgical specimens, using PCR. Samples with low tumour cell fraction were assigned to laser micro‐dissection (LMD). We found nine (4.5%) patients with EGFR mutation in the lung tumour resections, but failed to identify mutation in one of the corresponding pre‐operative, cytological specimens. Several (18.4%) analyses of the pre‐operative biopsies were inconclusive, especially in case of biopsies undergoing LMD and regarding exon 21 analysis. Discrepancy of mutation status in one patient may reflect intra‐tumoural heterogeneity or technical issues. Moreover, several inconclusive results in the diagnostic biopsies reveal that attention must be paid on the suitability of pre‐operative biopsies for EGFR mutation analysis. 相似文献